Inventor · Reinach, CH

Fritz Blatter

59Patents
10h-index
69Co-inventors
81Inventor score

Filing activity: Sep 11, 1996 → Jan 27, 2022

Most-cited inventions

PatentTitleAreaCited byStatus
US7923564B2 Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms Human Necessities 23 Active
US7732615B2 N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms Human Necessities 22 Active
US7868176B2 Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation Human Necessities 22 Active
US8236960B2 Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms Human Necessities 19 Active
US7727987B2 Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride Human Necessities 15 Expired
US7566714B2 Methods and compositions for the treatment of metabolic disorders Human Necessities 14 Expired
US9884857B2 Salts of dasatinib in amorphous form Chemistry; Metallurgy 13 Active
US8067416B2 Methods and compositions for the treatment of metabolic disorders Human Necessities 12 Active
US8318745B2 Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride Human Necessities 12 Active
US9993481B2 Methods and compositions for the treatment of metabolic disorders Human Necessities 11 Active
US9433624B2 Methods and compositions for the treatment of metabolic disorders Human Necessities 10 Active
US9556164B2 Salts of Dasatinib in crystalline form Chemistry; Metallurgy 7 Active
US9303036B2 Crystalline asenapine hydrochloride salt forms Human Necessities 7 Active
US9340536B2 Multicomponent crystals comprising dasatinib and selected co-crystal formers Chemistry; Metallurgy 7 Active
US9169262B2 Crystalline salts of Asenapine with organic di-acids and tri-acids Chemistry; Metallurgy 7 Active
US9567317B2 Multicomponent crystalline system comprising nilotinib and selected co-crystal formers Human Necessities 6 Active
US9796721B2 Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide Chemistry; Metallurgy 5 Active
US9394328B2 Crystalline dapagliflozin hydrate Chemistry; Metallurgy 4 Active
US8101800B2 5,6-dihydro-1H-pyridin-2-one compounds Chemistry; Metallurgy 4 Active
US8841316B2 Multicomponent crystalline system of rosuvastatin calcium salt and vanillin Chemistry; Metallurgy 3 Active
US8716305B2 Multicomponent crystalline system of rosuvastatin calcium salt and vanillin Chemistry; Metallurgy 3 Active
US8546602B2 5,6-D hydro-1H-pyridin-2-one compounds Chemistry; Metallurgy 3 Active
US7932387B2 Crystalline forms of rosuvastatin calcium salt Human Necessities 2 Active
US9290452B2 Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof Chemistry; Metallurgy 2 Active
US7928085B2 P-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazole[4,5-d]pyrimidine-2-one and methods for preparation Chemistry; Metallurgy 2 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.